Omnicell Inc. (OMCL) Hits New 52-week Low During January 20 Session

Equities Staff  |

Omnicell Inc. (OMCL) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $26.13, Omnicell Inc. dropped to $25.69 for a new 52-week low. By the closing bell, the company's stock was at $27.03 a share for a gain of 2.04%.

Falling to a new 52-week low is never fun for company's shareholder, but, depending on who you ask, it can be either a buy or a sell signal. Someone bearish on the stock might see it reaching its lowest price in a year as a sign of growing downward momentum and make sure they sell their shares. Bulls, though, are more likely to see a new 52-week low as the stock hitting its low point and anticipate a bounce in the share price.

However one plays it, it's often a critical moment for any stock and should be noted by investors.

Omnicell Inc. saw 117,626 shares of its stock trade hands, that's out of 35.43 million shares outstand. The stock has an average daily volume of 242,838 shares. After hitting a new 52-week low, Omnicell Inc. enters the new trading day with a market cap of 957.62 million, a 50-day SMA of $28.64 and a 200-day SMA of $33.56

Omnicell Inc. now has a P/E ratio of 30.1.

For a complete fundamental analysis analysis of Omnicell Inc., check out’s Stock Valuation Analysis report for OMCL. To see the latest independent stock recommendations from’s analysts, visit our Research section.

Omnicell Inc provides automation & business information solutions to update medication administration process & manage costly medical supplies for operational efficiency & patient safety. Its operating business segments are acute care & non-acute care.

Omnicell Inc. has 1,236 employees, is led by CEO Randall A. Lipps, and makes its home in Mountain View, CA.

Omnicell Inc. is also a component of the Russell 2000 Index, which is generally viewed as the most reliable indicator of the health of the broader small-cap market. Using a rules-based methodology, it creates a simple, unbiased view of how America's stable of smaller publicly traded companies are performing in the stock markets.

The index consists of the 2,000 smallest companies of the 3,000 largest publicly-traded companies in the country as judged by market cap. It's constructed by Russell Investments, which also builds and maintains the Russell 3000 (an index consisting of all 3,000 biggest companies by market cap) and the large-cap Russell 1000 (which has the 1,000 largest companies from the Russell 3000).

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update.

Emerging Growth

Investview Inc

Investview Inc is an investor technology and education company. It provides products that allow the individual investor to find, analyze, track, and manage their portfolio.